^
12d
Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort. (PubMed, Lancet)
Patients with rare kidney diseases differ from the general population of individuals with chronic kidney disease: they have higher 5-year rates of kidney failure but higher survival than other patients with chronic kidney disease stages 3-5, and so are over-represented in the cohort of patients requiring kidney replacement therapy. Addressing unmet therapeutic need for patients with rare kidney diseases could have a large beneficial effect on long-term kidney replacement therapy demand.
Journal
|
RaDaR™ assay
23d
Tracking triple negative breast cancer (TNBC) evolution in the molecular residual disease (MRD) setting in the c-TRAK TN clinical trial (AACR 2024)
Polyclonal metastasis is a common mode of metastasis in TNBC, with frequent detection of primary tumor subclones in the metastasis. NAC provides an evolutionary bottleneck, with subclones detected post NAC being the most likely to persist into the MRD and subsequent relapse. Relapsed cancer frequently had subclones not detected in the primary cancer, with approximately half of these potentially late arising, and half detectable in MRD suggesting early establishment of diversity.
Clinical
|
RaDaR™ assay
23d
Longitudinal ctDNA monitoring using a high sensitivity tumor-informed assay in patients with metastatic HR+/HER2- breast cancer receiving endocrine therapy and CDK4/6 inhibitors (AACR 2024)
RaDaR enabled sensitive ctDNA monitoring in 91% HR+/HER2- mBC pts on ET + CDK4/6i. ctDNA levels were prognostic and fell rapidly with therapy, but suppression occurred in less than one-third of pts, taking a median of 5.2 mo. Pts with negative/decreasing ctDNA may require less frequent clinical/radiographic tumor evaluations.
Clinical • Circulating tumor DNA • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
RaDaR™ assay
1m
Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck. (PubMed, Cell Death Differ)
The RaDaR assay but not CAPP-seq may detect MRD in patients who relapse within 1 year. HPV-seq may be more sensitive than dPCR for MRD detection.
Journal • Metastases
|
RaDaR™ assay • SafeSEQ HPV Test
2ms
Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial (YIR 2024)
Background: The PENELOPE-B phase III trial investigated the addition of one year of palbociclib to endocrine therapy (ET), in patients with hormone receptor positive HER2 negative breast cancer with residual invasive disease after neoadjuvant chemotherapy... Detection of ctDNA following neoadjuvant chemotherapy, and surgery, is associated with a very high risk of early relapse suggesting limited efficacy of adjuvant ET. Clinical imaging and studies of experimental therapy are warranted in this patient population. Testing ctDNA after recent neoadjuvant chemotherapy in luminal-A like breast cancer has relatively low ‘sensitivity’ for predicting future relapse, in particular for later relapses, in part suggesting that response to neoadjuvant chemotherapy may reduce ctDNA detection
Clinical • Surgery • Circulating tumor DNA
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • ER positive + HER-2 negative • PTEN mutation + HR positive
|
RaDaR™ assay
|
Ibrance (palbociclib)
3ms
NeoGenomics to appeal ruling (NeoGenomics Press Release)
"NeoGenomics, Inc...announced that NeoGenomics Laboratories, Inc., a subsidiary of NeoGenomics Inc., will appeal the preliminary injunction issued by the United States District Court for the Middle District of North Carolina."
Corporate lawsuit • Patent
|
RaDaR™ assay
3ms
Natera wins preliminary injunction in patent infringement lawsuit against NeoGenomics Radar test (Natera Press Release)
"Natera, Inc...announced that the federal District Court for the Middle District of North Carolina has issued a preliminary injunction, effective immediately, enjoining the RaDaR assay from NeoGenomics Labs, Inc."
Corporate lawsuit • Patent
|
RaDaR™ assay
4ms
NeoGenomics to present new data at San Antonio Breast Cancer Symposium highlighting utility of RaDaR for therapy response (NeoGenomics Press Release)
"NeoGenomics, Inc...announced new data highlighting its RaDaR assay for minimal residual disease (MRD) will be presented at the 46th annual San Antonio Breast Cancer Symposium (SABCS)."
Clinical data
|
RaDaR™ assay
5ms
Longitudinal Neoadjuvant and Post-operative Evaluation of Circulating Tumor DNA in Early Breast Cancer using a Tumor-Informed Assay: Updated Analysis of the TRACER Cohort (SABCS 2023)
RaDaR detects ctDNA in most patients prior to the initiation of NAT for EBC. Changes in ctDNA levels during treatment and its presence are associated with clinical outcomes. Prospective evaluation and integration of RaDaR testing into clinical trials are warranted.
Clinical • Circulating tumor DNA
|
HER-2 (Human epidermal growth factor receptor 2)
|
RaDaR™ assay
6ms
Unveiling the Disproportionate Impact of Rare Kidney Diseases on Kidney Failure: A Longitudinal Analysis Using the UK National Registry of Rare Kidney Diseases (RaDaR) (KIDNEY WEEK 2023)
Patients with rare kidney diseases differ from the general CKD population: they are more likely to reach ESKD and half as likely to die with CKD stages 3-5, so are disproportionately represented in the RRT population. Successfully addressing unmet need in rare diseases may therefore have a disproportionate effect on RRT demand long term.
RaDaR™ assay
6ms
Rate of Loss of eGFR and Time-Averaged Proteinuria in IgA Nephropathy (IgAN) Patients Progressing from Early-Stage Disease to Kidney Failure (KIDNEY WEEK 2023)
Given the comparability of eGFR decline prior to and after passing an eGFR of 45ml/min/1.73m2, slope measurements in early disease stages may be useful in estimating future eGFR loss. Comparability of eGFR slopes but differences in TA-PU suggest patients with stable rates of eGFR loss suffer increasing damage to the glomerular filtration barrier.
Clinical
|
RaDaR™ assay
6ms
Patient Characteristics and Renal Outcomes of C3 Glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) in the UK: A Retrospective Analysis of 287 Patients in the UK National Registry of Rare Kidney Diseases (RaDaR) (KIDNEY WEEK 2023)
RaDaR is a large and robust data source allowing investigation into C3G/IC-MPGN natural history. We found heterogeneity of current treatment approaches in this cohort and rapid progression to kidney failure despite current treatments.
Retrospective data
|
RaDaR™ assay
6ms
Levels of Socioeconomic Deprivation Are Associated with Worse Kidney Outcomes in Patients with IgA Nephropathy: Data from UK RaDaR (KIDNEY WEEK 2023)
Outcomes in this large IgAN cohort have been published and shown to be poor with few patients expected to avoid kidney failure in their lifetime. This analysis demonstrates even worse outcomes if more socioeconomically deprived & highlights the need to develop strategies to ensure equity of access not only to early diagnosis but also to the new therapies that are showing promise in preventing kidney failure in IgAN.IMD QuintilesAge at diagnosis(median, 25th & 75th pctl)Gender (M/F)(% IMD quintile)White/ non-White (%)eGFR at diagnosis(median, 25th & 75th pctl)Time to kidney failure(median, 95% CI)1- most deprived38.9 (28.4, 51.2)67.3/32.775.2/25.838 (21, 69)7.9 (6.9, 9.3)341.0 (29.4, 51.9)69.9/30.186.2/13.839 (22, 70)10.4 (9.0, 12.6)5- least deprived41.6 (30.6, 55.0)74.3/25.788.5/11.537 (22, 68)12.4 (11.1, 13.5)
Clinical
|
RaDaR™ assay
7ms
Supporting Precision Medicine with Advanced Sequencing Offerings for Solid Tumor and Hematologic Malignancies (AMP 2023)
Precision medicine has become increasingly important for management of cancer patients including comprehensive genomic profiling (CGP) and molecular residual disease (MRD). Join us to learn more about NeoGenomics suite of advanced sequencing tests.NeoComprehensive™ – Solid Tumor and NeoComprehensive™ – Myeloid leverage both DNA and RNA sequencing analysis to detect multiple classes of genomic alterations that are relevant for diagnosis, therapy selection, prognosis, and clinical trials.RaDaR® is a personalized liquid biopsy test for the detection of MRD and recurrence, detecting the trace amounts of ctDNA that remain after surgery or other curative intent treatment, and early signs of relapse.
Metastases
|
Neo Comprehensive - Solid Tumor Assay • RaDaR™ assay
8ms
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
RaDaR™ assay
|
Nerlynx (neratinib) • Kadcyla (ado-trastuzumab emtansine)
8ms
Natera files patent infringement suit against NeoGenomics (Natera Press Release)
"Natera, Inc...announced that it has filed a lawsuit in the North Carolina Federal District Court against NeoGenomics Labs, Inc. ('NeoGenomics') for infringement of Natera’s U.S. Patent Nos. 11,519,035 and 11,530,454 by NeoGenomics’ RaDaR molecular residual disease assay."
Corporate lawsuit • Patent
|
RaDaR™ assay
8ms
mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response (ESMO 2023)
There was a trend for enhanced efficacy of mRNA-4157 + pembro across BRAF V600E/K WT (n=96) (HR [95% CI]: 0.808 [0.366–1.784]) and MUT (n=61) subpopulations (0.332 [0.130–0.850]); however, considering ctDNA status by focusing on ctDNA-negative subpopulation increased similarity of efficacy across BRAF WT (n=68) and MUT (n=42) subgroups (0.334 [0.121–0.923] vs 0.069 [0.009–0.563]). Table: LBA49 ctDNA subgroup Patient criteria Molecular responders Patients with MRD at baseline that resolved during treatment (ctDNA positive at treatment initiation became ctDNA negative) OR Patients with no MRD at baseline that became ctDNA positive on treatment (MRec), and then ctDNA negative again Molecular non-responders Patients with MRD at baseline that did not resolve during treatment (ctDNA positive at treatment initiation and stayed positive) OR Patients with no MRD at baseline who showed molecular progression (MRec, ctDNA negative at treatment initiation became ctDNA positive and stayed positive) Conclusions These results suggest a potential relationship between ctDNA dynamics and treatment outcomes in pts with high-risk resectable melanoma and support further exploration in upcoming planned studies.
Late-breaking abstract • Clinical
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600 • BRAF V600K • BRAF wild-type
|
RaDaR™ assay
|
Keytruda (pembrolizumab) • mRNA-4157
8ms
NeoGenomics announces medicare coverage for RaDaR assay for minimal residual disease and recurrence in breast cancer (NeoGenomics Press Release)
"NeoGenomics, Inc...announced today that the Molecular Diagnostics Services Program (MolDx) has conveyed coverage for the RaDaR assay, a personalized liquid biopsy for minimal residual disease (MRD) and recurrence detection...Following this decision, effective as of March 24, 2023, the RaDaR assay is now covered for fee-for-service Medicare patients within the United States with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer."
Medicare • Reimbursement
|
RaDaR™ assay
8ms
Longitudinal ctDNA Testing in Resected, Early Stage Non-small Cell Lung Cancers (IASLC-WCLC 2023)
In patients with early stage NSCLC (small, node negative tumors), 25% have detectable ctDNA pre-operatively. Surgical resection led to ctDNA clearance in 94% of cases. Our results support ongoing testing beyond the initial MRD landmark in patients with surgically resected disease.
Circulating tumor DNA
|
PD-L1 (Programmed death ligand 1)
|
RaDaR™ assay
10ms
NeoGenomics RaDaR assay for minimal residual disease receives first commercial coverage (NeoGenomics Press Release)
"NeoGenomics, Inc...announced that its RaDaR assay, a personalized liquid biopsy for minimal/molecular residual disease (MRD) and recurrence detection, has obtained its first pan-cancer commercial coverage by Blue Shield of California."
Commercial
|
RaDaR™ assay
10ms
NeoGenomics and German Breast Group announce new data demonstrating clinical potential of the RaDaR MRD assay in HR+/HER2- breast cancer (NeoGenomics Press Release)
"NeoGenomics, Inc...announced new data in support of its RaDaR assay for the detection of molecular residual disease (MRD) and recurrence in patients with high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer."
Clinical data
|
RaDaR™ assay
10ms
NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO (NeoGenomics Press Release)
"NeoGenomics, Inc...announced new data supporting its cancer tests and treatment guidance tools will be showcased in five poster presentations at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting taking place June 2-6 in Chicago, Illinois....Posters showcasing NeoGenomics' MRD and recurrence monitoring efforts include a Trials in Progress presentation for what is believed to be a first-in-its-kind MRD-directed interventional study in high risk, early stage HER2+ breast cancer, 'KAN-HER2 MRD' (NCT05388149)....Also being presented are findings from five studies using the RaDaR MRD assay in lung, breast, and head and neck cancers, as well as the InVisionFirst®-Lung liquid biopsy in metastatic non-small cell lung cancer."
Trial status • Clinical data • P3 data
|
RaDaR™ assay
|
Ibrance (palbociclib) • Nerlynx (neratinib) • Kadcyla (ado-trastuzumab emtansine)
11ms
Multimodal detection in plasma of molecular residual disease (MRD) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). (ASCO 2023)
HPV DNA and ctDNA can be detected in LA-HNSCC before and after definitive therapy. RaDaR but not CAPP-seq may detect MRD in pts who relapse within 1 year after RT/CRT with a significant lead time. HPV-seq may be more sensitive than dPCR to detect HPV DNA in MRD.
Metastases
|
RaDaR™ assay • SafeSEQ HPV Test
11ms
Minimal residual disease by circulating tumor DNA as a biomarker of recurrence free survival in resected high-risk melanoma patients treated with mRNA-4157/V940, a personalized cancer vaccine, and pembrolizumab. (ASCO 2023)
MRD detection by plasma ctDNA assay at the start of adjuvant melanoma treatment is uncommon in mRNA4157-p201 but is associated with shorter RFS. Treatment with the combination of mRNA-4157/V940 and pembrolizumab was associated with prolonged RFS compared to pembrolizumab monotherapy in patients with high-risk resectable melanoma, irrespective of MRD status Additional analyses including assessment of longitudinal ctDNA patterns are ongoing. The association between MRD and mRNA-4157/V940 treatment effect will be further explored in upcoming planned studies.
Late-breaking abstract • Clinical • PD(L)-1 Biomarker • Minimal residual disease • Circulating tumor DNA
|
RaDaR™ assay
|
Keytruda (pembrolizumab) • mRNA-4157
11ms
Validation of recurrence prediction using circulating tumor DNA in patients with curatively treated early stage non-small cell lung cancer. (ASCO 2023)
ctDNA detection by RaDaR assays predicted recurrence in two independent cohorts, confirming the potential to identify patients for adjuvant treatment. In stage I patients with positive ctDNA, adjuvant treatment could be offered with confidence due to high specificity of 99% and PPV of 91%. In stage II-III patients, the primary cancer recurred in a quarter of patients with no ctDNA detected post-treatment (NPV 74%).
Clinical • Circulating tumor DNA
|
RaDaR™ assay
11ms
A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD). (ASCO 2023)
KAN-HER2 represents the first reported MRD-directed interception trial for HER2-positive breast cancer. Clinical trial information: NCT05388149.
P2 data • Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
RaDaR™ assay
|
Nerlynx (neratinib) • Kadcyla (ado-trastuzumab emtansine)
11ms
Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial. (ASCO 2023)
Background: The PENELOPE-B phase III trial investigated the addition of one year of palbociclib to endocrine therapy (ET), in patients with hormone receptor positive HER2 negative breast cancer with residual invasive disease after neoadjuvant chemotherapy... Detection of ctDNA following neoadjuvant chemotherapy, and surgery, is associated with a very high risk of early relapse suggesting limited efficacy of adjuvant ET. Clinical imaging and studies of experimental therapy are warranted in this patient population. Testing ctDNA after recent neoadjuvant chemotherapy in luminal-A like breast cancer has relatively low ‘sensitivity’ for predicting future relapse, in particular for later relapses, in part suggesting that response to neoadjuvant chemotherapy may reduce ctDNA detection.
Clinical • Surgery • Circulating tumor DNA
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • ER positive + HER-2 negative
|
RaDaR™ assay
|
Ibrance (palbociclib)
11ms
Circulating tumor DNA (ctDNA) monitoring in patients with breast cancer receiving neoadjuvant palbociclib and endocrine therapy: A secondary analysis of the NeoRHEA phase 2 study. (ASCO 2023)
Detection of ctDNA in early-stage breast cancer is challenging. Our data suggests association of ctDNA detection with some pathological and clinical variables. Independent validation is needed.
P2 data • Clinical • Circulating tumor DNA
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 negative
|
RaDaR™ assay
|
Ibrance (palbociclib)
12ms
NeoGenomics to share nine abstracts at the American Association of Cancer Research (AACR) annual meeting 2023 (NeoGenomics Press Release)
"NeoGenomics, Inc...announced today that the company and its collaborators will present a total of nine abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2023 taking place April 14-19, 2023 in Orlando, Florida...NeoGenomics, alongside collaborators, will present new data demonstrating the broad portfolio of services and available validated assays focused on tumor biology, including the use of RaDaR, a personalized, highly-sensitive liquid biopsy sequencing test for the detection of minimal residual disease (MRD) and recurrence."
Clinical data
|
RaDaR™ assay
1year
NeoGenomics announces commercial availability of the RaDaR molecular residual disease test (NeoGenomics Press Release)
"NeoGenomics...announced today the commercial availability of the RaDaR® assay, a liquid biopsy test for molecular/minimal residual disease (MRD). MRD is the trace amounts of circulating tumor DNA (ctDNA) that remain after surgery or other cancer treatment."
Commercial
|
RaDaR™ assay
1year
Evaluation of a tumor informed MRD assay with contrived breast cancer samples (AACR 2023)
The RaDaR assay showed high sensitivity for pan-cancer as well as ER+ breast cancer, which is known to have a low TMB compared to other subtypes. In this albeit small LoD study the Inivata assay was highly sensitive for the detection of ctDNA which is imperative to confidently detect ctDNA in advance of overt clinical recurrence.
TMB (Tumor Mutational Burden)
|
TMB-L
|
RaDaR™ assay
1year
ctDNA dynamics in early stage node negative lung cancers (AACR 2023)
In patients with early stage NSCLC (small node negative tumors), 24% have detectable ctDNA pre-operatively. Surgical resection led to ctDNA clearance in 93% of cases. Our results support ongoing testing beyond the initial MRD landmark.
Circulating tumor DNA
|
RaDaR™ assay
1year
RaDaR assay demonstrates clinical potential for helping oncologists determine whether or not muscle-invasive bladder cancer patients undergo radical surgery (NeoGenomics Press Release)
"NeoGenomics, Inc...announced results of a new study of the RaDaR® assay in patients with muscle-invasive bladder cancer immediately following treatment with a combination of the immune checkpoint inhibitors in the neoadjuvant setting. Plasma and urine collected from the patients during treatment was analyzed."
Clinical data
|
RaDaR™ assay
over1year
Natera files second patent infringement suit against NeoGenomics subsidiary Inivata (Genomeweb)
"Natera on Tuesday filed a lawsuit against NeoGenomics subsidiary Inivata, claiming infringement of a new patent it was issued that same day...In a complaint filed with the US District Court of Delaware, Natera alleged that Inivata has unlawfully used its patented technology, covered by US Patent No. 11,530,454, to create its Radar assay, a tumor-informed test for detecting and monitoring residual cancer in patient blood samples."
Patent
|
RaDaR™ assay
over1year
RaDaR(R) assay demonstrates clinical potential for detecting disease recurrence across all types of early breast cancer, including triple negative disease (NeoGenomics Press Release)
"NeoGenomics, Inc...and its liquid biopsy-focused subsidiary, Inivata Limited ('Inivata') today announced that new data, being presented at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) taking place on December 6-10, support the use of the RaDaR Assay across all types of early breast cancer in both the adjuvant and surveillance settings."
Clinical data
|
RaDaR™ assay
over1year
Trial initiation date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
RaDaR™ assay
|
Nerlynx (neratinib) • Kadcyla (ado-trastuzumab emtansine)
over1year
NeoGenomics provides update on MolDX submission for CRC and RaDaR(TM) commercial launch (NeoGenomics Press Release)
"NeoGenomics, Inc...is providing an update on its discussions with MolDX and on its commercial launch activities for RaDaR, its proprietary assay for the detection of minimal residual disease (MRD) and recurrence...Late last week, MolDX informed the Company that additional clinical evidence is needed in order to secure Medicare coverage for RaDaR for Colorectal Cancer (CRC). Specifically, MolDX asked for a direct comparison with other MRD tests being utilized or a full clinical study."
Launch • Reimbursement
|
RaDaR™ assay
over1year
Circulating tumour DNA (ctDNA) detection and dynamics in patients with early breast cancer (EBC): Results of the neoadjuvant TRACER cohort (SABCS 2022)
RaDaR demonstrated high sensitivity for ctDNA prior to treatment in patientsreceiving neoadjuvant therapy for EBC, permitted dynamic monitoring of treatment effect, andidentified patients with persistent ctDNA after curative-intent therapy, as well as ctDNAemergence prior to clinical recurrence. Full results for the TRACER cohort and analysis ofclinical covariates will be presented at the meeting.
Clinical • Circulating tumor DNA
|
HER-2 negative
|
RaDaR™ assay
over1year
Comparison of a personalized sequencing assay and digital PCR for circulating tumor DNA based Molecular Residual Disease detection in early-stage triple negative breast cancer in the cTRAK-TN trial (SABCS 2022)
The cTRAK-TN trial recruited 161 pts into prospective ctDNA surveillance with dPCR, with ctDNA positive pts randomised to 1) CT staging plus pembrolizumab therapy for patients without relapse or 2) observation... The RaDaR personalised multi-mutation sequencing assay detected MRD with a longer median lead time prior to relapse, and with higher sensitivity, than dPCR mutation tracking assays. These findings have implications for the choice of ctDNA assay in clinical trials designed to treat patients at the point of MRD detection.
PD(L)-1 Biomarker • Circulating tumor DNA
|
RaDaR™ assay
|
Keytruda (pembrolizumab)
over1year
NeoGenomics and liquid biopsy subsidiary Inivata and collaborators to present new data at ESMO Congress 2022 (NeoGenomics Press Release)
"NeoGenomics, Inc...today announces that its liquid biopsy focused subsidiary Inivata Limited ('Inivata'), alongside collaborators, will present new data on its RaDaR™ assay for the detection of minimal residual disease (MRD) and recurrence at the European Society for Medical Oncology (ESMO) Congress, taking place September 9th-13th, 2022. NeoGenomics and Inivata will host a joint booth in the exhibition hall at the conference."
Clinical data
|
RaDaR™ assay
over1year
Inivata and Collaborators to Present New Data to Support the Application of RaDaR MRD Assay Across Tumor Types at ESMO Congress 2022 (Inivata Press Release)
"Inivata...will present new data on its RaDaR™ assay for the detection of minimal residual disease (MRD) and recurrence at the European Society for Medical Oncology (ESMO) Congress, taking place on 9-13 September 2022. Inivata and NeoGenomics, Inivata’s parent company, will host a joint booth in the exhibition hall at the conference. Data will be presented from the single-center prospective cohort ‘LIONESS’ study in head and neck squamous cell carcinoma (HNSCC) patients receiving primary surgery with curative intent. The study demonstrated that the RaDaR assay was able to detect ctDNA in 100% of cases with confirmed clinical recurrences, highlighting the significant potential of the assay to guide treatment decisions and improve disease outcome."
Clinical data
|
RaDaR™ assay
over1year
TREAT ctDNA Elacestrant (clinicaltrials.gov)
P3, N=220, Not yet recruiting, European Organisation for Research and Treatment of Cancer - EORTC
New P3 trial • Circulating tumor DNA
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • ER positive + HER-2 negative
|
RaDaR™ assay
|
tamoxifen • letrozole • anastrozole • exemestane • Orserdu (elacestrant)